0000000000164935

AUTHOR

Alice Bartolini

showing 1 related works from this author

Genetic and pharmacological modulation of DNA mismatch repair heterogeneous tumors promotes immune surveillance.

2023

Patients affected by colorectal cancer (CRC) with DNA mismatch repair deficiency (MMRd), often respond to immune checkpoint blockade therapies, while those with mismatch repair-proficient (MMRp) tumors generally do not. Interestingly, a subset of MMRp CRCs contains variable fractions of MMRd cells, but it is unknown how their presence impacts immune surveillance. We asked whether modulation of the MMRd fraction in MMR heterogeneous tumors acts as an endogenous cancer vaccine by promoting immune surveillance. To test this hypothesis, we use isogenic MMRp (Mlh1+/+) and MMRd (Mlh1-/-) mouse CRC cells. MMRp/MMRd cells mixed at different ratios are injected in immunocompetent mice and tumor reje…

Cancer Research6-thioguaninemismatch repairOncology6-thioguanine; heterogeneity; immune checkpoint blockade; immune evasion; immune surveillance; microsatellite unstable tumors (MSI); mismatch repair; temozolomide6-thioguanine heterogeneity immune checkpoint blockade immune evasion immune surveillance microsatellite unstable tumors (MSI) mismatch repair temozolomideimmune surveillancemicrosatellite unstable tumors (MSI)temozolomideheterogeneityimmune checkpoint blockadeSettore MED/08 - Anatomia Patologicaimmune evasionCancer cell
researchProduct